BI 765845: Heart disease modulator | Myocardial infarction
BI 765845: Heart disease modulator | Myocardial infarction
Search
Feline diabetes: how to detect and treat it
What are the symptoms of diabetes in cats, and how do you manage this chronic disease? Find the answers here.
WW Contacts Human Pharma OCTOBER 2024 CORP_4.pdf
BI 1291583: CatC Inhibitor
BI 1291583: CatC Inhibitor
Phospholipid modulator
Phospholipid modulator
Vascular modulator
Vascular modulator
Ion channel inhibitor
Immunomodulator
Zongertinib (BI 1810631): HER2 Tyrosine Kinase Inhibitor (TKI) | NSCLC
Zongertinib (BI 1810631): HER2 Tyrosine Kinase Inhibitor (TKI) | NSCLC
KRAS multi-inhibitor
Phospholipid modulator
Partnering in Mental Health Disorders HP OCTOBER 2024 CORP.pdf
Vascular modulator
Partnering in Cardio-Renal-Metabolic HP OCTOBER 2024 CORP.pdf
Partnering with Boehringer Ingelheim HP OCTOBER 2024 CORP.pdf
Partnering in Immunology & Resp HP OCTOBER 2024 CORP.pdf
October 2024 Pipeline
Lysophospholipase inhibitor
Lysophospholipase inhibitor
Lysophospholipase inhibitor
CARMELINA-elderly-analysis
CARMELINA® outcome trial subgroup analysis demonstrates long-term cardiovascular and renal safety data in older people with type 2 diabetes
empa-reg-outcome-recurrent-events
EMPA-REG OUTCOME® analysis: Empagliflozin reduced risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and CV disease
Generalized pustular psoriasis: Unmet needs
Dr Clerisme-Beaty and Dr Strober MD, PhD discuss the impact of living with GPP including unseen challenges and future management.
World water day 2019
Boehringer Ingelheim started a social project in Mexico to preserve the aquifer and to ensure the water supply for dog shelters. Rainwater collector will save 180,000 liters of rainwater every year.
European Commission approves SPEVIGO® (spesolimab) for generalized pustular psoriasis flares
European Commission grants marketing authorization for spesolimab, the first specific treatment option for generalized pustular psoriasis flares in adults
Spesolimab prevents GPP flares
Spesolimab prevents generalized pustular psoriasis flares in EFFISAYIL™ 2 trial